A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

National Launch of the ShurFit 2C Interbody Systems Featuring Titanium Plasma Spray and Hydroxyapatite Coating

ShurFit 2C Interbody Systems: Precision Spine, Inc. has launched nationally the ShurFit ACIF 2C Anterior Cervical, TLIF 2C, and TPLIF 2C Posterior Interbody Systems, which is made from medical grade polyetheretherketone (Peek Optima, LT1) and coated with both commercially pure Titanium (Ti) and Hydroxyapatite (HA).

“The ShurFit 2C Interbody System’s distinguishing feature is its unique coating of both Titanium and Hydroxyapatite that helps increase durability and makes enhanced fixation possible while the process of biologic fusion takes place,” said Stephen D. Cook, Ph.D., Executive Director and Founder of the Fellowship of Orthopaedic Researchers, who was instrumental in the design and development of the device with Precision Spine engineers.

The ShurFit 2C coating technology combines a high-strength PEEK core with a unique, dual layer of coatings applied directly to the endplate surfaces. A biocompatible plasma-sprayed CP Titanium coating, with an outer layer of osteoconductive Hydroxyapatite, provides an optimal environment for osseointegration. The dual coating promotes rapid bone formation, which offers implant stability, less potential for implant migration, and the formation of a stable fusion mass while strategically placed tantalum markers facilitate radiographic implant positioning.

“The ShurFit ACIF 2C Systems are an important addition to our growing portfolio of devices,” said Chris DeNicola, Chief Operating Officer of Precision Spine, “and is further evidence of Precision Spine’s continuing commitment to work with surgeons in the design and commercialization of advanced products that utilize the latest technology to help bring greater versatility, efficiency, and cost-effectiveness to the OR.”

The ShurFit ACIF 2C system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine at one disc level and consists of implants with various heights to accommodate individual patient anatomy and graft material size. It is implanted from the anterior approach at the C3 to C-7 disc levels and is designed to be packed with autogenous bone graft to help facilitate fusion while providing mechanical support to the implanted level until biologic fusion is achieved.

The ShurFit TLIF 2C and TPLIF 2C Interbody Fusion Devices are indicated for intervertebral body fusion of the spine in skeletally mature patients. The device system is designed for use with autograft to facilitate fusion. One device is used per intervertebral space for the TLIF 2C and TPLIF 2C system. Two devices are used per intervertebral space for the PLIF 2C system.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy